“…The primary hypothesis was that, although total levels of circulating CTRP3 will be similar between people with type 2 diabetes compared with nondiabetic controls, there will be a difference between groups in the circulating oligomeric state of CTRP3. The secondary purpose of this study was to determine whether the circulating oligomeric state of CTRP3 correlates with the circulating levels of inflammatory cytokines or triglycerides as CTRP3 has been previously demonstrated to attenuate inflammation and to reduce triglyceride levels (Hofmann et al, ; Kopp, Bala, Buechler, et al, ; Kopp, Bala, Weigert, et al, ; Li et al, ; Petersen et al, ; Peterson et al, , ; Schmid, Kopp, Hanses, Karrasch, & Schaffler, ; Tan et al, ; Trogen et al, ; Yang et al, ; Yoo et al, ).…”